Just a moment, the page is loading...

GSK-49653/207




A 24-week Randomized, Double-blind, Active-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rosiglitazone When Administered to Pediatric Patients with Type 2 Diabetes Mellitus
rosiglitazone
49653/207
Diabetes Mellitus, Type 2
Phase 3
A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.
March 2015